Weak to moderate PSMA immunoreactivity of PDAC tumor cells was detected in 5.3% of cases (Figure 1(a)), while PSMA expression in tumor-associated neovasculature (cutoff PSMA+/CD34+ vessel ratio > 0.05) could be detected in 63.2% (weak/moderate in 33.4% and strong in 29.8% of cases, resp). Here, CD34 is linked to neoplasm.